A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
John Obaro, group managing director (GMD) of SystemSpecs, says the company remains dedicated to developing technology solutions for businesses and governments.
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
This year, one of the best watches unveiled at the show was a new Zenith Chronomaster Sport model. That was one of a pair of chronographs launched by the brand, and features a gem-set bezel complete ...
In today's episode of Fratello Talks, the guys discuss this year's LVMH Watch Week ✓ Tune in to hear about all the new releases! ✓ ...
After a quick pivot away from its original LA venue, LVMH presented nine of its watch brands to press in New York. There, ...
Although street encampments and public drug use are top issues for Portland residents, the new City Council and mayor have ...
Justin Horowitz has been surfing the IOS wave with clients for five years now as it becomes an increasingly institutionalized ...
The Eola-Amity Hills Winegrowers Association is thrilled to announce the finalized lineup for its highly anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback